Skip to content
Screener

Versigent VGNT Cash & Equivalents

Cash & Equivalents at other companies

BK
BKBK
$9.49B+12.8%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$3.08M+1,132%
Veradermics logo
VeradermicsMANE
$168.41M+419%
Schering-Plough logo
Schering-PloughSGP
$238.9M+312%
Dollar General logo
Dollar GeneralDG
$1.35B+59.2%
Target logo
TargetTGT
$3.53B+22.4%

Other financials

Income statement

See full
Revenue$2.2B+9.3%
Gross profit$244.0M-2.0%
Operating income$74.0M-39.8%
Net income$78.0M-17.9%

Balance sheet

See full
Total debt$2.4B
Total equity-$48.0M-103%
Total assets$4.9B

Cash flow

See full
Operating cash flow$36.0M-10.0%
CapEx$66.0M+78.4%
Free cash flow-$30.0M-1,100%

Valuation

See full
Market cap$3.03B+51.9%
Enterprise value$5.15B

Returns & leverage

See full
Debt / equity0.2×
Current ratio1.4×

Where this comes from

Reported directly by Versigent in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Versigent’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 5:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0002078008-26-000008
Line itemMarch 31,2026December 31,2025
(in millions)
ASSETS
Current assets:
Cash and cash equivalents$282$276
Accounts receivable, net (Note 2)
Outside customers net of allowance for doubtful accounts of $17 million and $17 million, respectively1,7131,518
Related parties11649
Inventories (Note 4)784772

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Versigent's cash & equivalents?
Versigent (VGNT) reported cash & equivalents of $282M in Q1 2026.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Versigent's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude